Introduction/Overview
Natural products, as an important source of drug discovery and development, play an irreplaceable role in the history of human disease treatment. Among them, anthraquinone compounds have attracted much attention due to their wide range of biological activities. Rubiadin (CAS number: 117-02-2), as a natural anthraquinone derivative derived from various plants in the Rubiaceae family, has become a hot topic in natural product pharmacology research in recent years due to its multi-target and multi pathway pharmacological effects. This compound not only exhibits classic anti-inflammatory and antioxidant properties, but also shows great potential in multiple cutting-edge fields such as anti-tumor, antiviral, anti osteoporosis, and neuroprotection. Its core mechanism of action involves the inhibition of the nuclear factor kappa B (NF - κ B) signaling pathway and the regulation of multiple key targets such as AMPK, STAT3, BCL-2 family proteins, thereby intervening in the pathological processes of various major diseases. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, molecular mechanisms of action, pharmacological evaluation, and clinical application prospects of methyl isoquercetin, in order to provide comprehensive scientific references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
Methyl isoquercetin, chemical name 1,3-dihydroxy-2-methylanthraquinone, molecular formula C15H10O4, molecular weight 254.2410. Its basic skeleton is anthraquinone, with one phenolic hydroxyl group at positions 1 and 3, and one methyl substituent at position 2. This structure endows it with typical polyketide compound characteristics and is also the chemical basis for its various biological activities.
From the analysis of physical and chemical properties, the lipid water partition coefficient (LogP) of methyl isoquercetin is 3.0343, indicating its lipophilicity, which is beneficial for its penetration of cell membranes but may also affect its water solubility. Its topological polar surface area (TPSA) is 74.6000 Å ², which is relatively moderate. The water solubility data (0.0661) confirms that it belongs to a poorly soluble compound, which is a key consideration in its formulation development. Preliminary drug risk assessment shows that its blood-brain barrier permeability is low, suggesting that its direct effects on central nervous system diseases may be limited, but it may also reduce the risk of central side effects. Importantly, its hERG inhibitory activity is negative, indicating a low potential risk of arrhythmia; The Ames test result is 1.2, indicating a low risk of mutagenicity, which provides favorable preliminary safety data for its subsequent development.
Plant sources and extraction methods
Methyl isorubicin is widely present in plants of the Rubiaceae family, especially in the Rubia genus. Rubia cordifolia is its classic source, and the compound name "Rubiadin" is derived from it. In addition, it has also been found in plants such as Morinda and Galium. These plants are commonly used in traditional medicine for promoting blood circulation, removing blood stasis, reducing inflammation, and relieving pain. Some of their medicinal effects may be related to anthraquinone components such as methyl isoquercetin.
The extraction of methyl isoquercetin from plant materials is often carried out using organic solvent extraction method. The typical process includes crushing dried plant roots or whole plants, and using polar organic solvents such as methanol, ethanol, or acetone for reflux extraction or ultrasound assisted extraction. After vacuum concentration, the crude extract can be preliminarily purified by acid-base treatment using its anthraquinone compound characteristics (for example, by utilizing the acidity of its phenolic hydroxyl group for alkaline dissolution and acid precipitation). Further purification relies on column chromatography techniques such as silica gel column chromatography, polyamide column chromatography, or high-performance liquid chromatography (HPLC) to separate high-purity methyl isoquercetin monomers. Modern extraction techniques such as supercritical fluid extraction are also being explored to improve extraction efficiency and selectivity.
Pharmacological activity research
Methyl isorubicin exhibits remarkable multidimensional pharmacological activities, covering multiple aspects such as anti-inflammatory, antioxidant, anti-tumor, anti osteoporosis, liver protection, anti infection, and neuroprotection.
- Anti inflammatory and antioxidant activity Methyl isoquercetin is an effective free radical scavenger that can significantly inhibit lipid peroxidation and alleviate oxidative stress damage. Its anti-inflammatory effect is outstanding, and it can effectively reduce the levels of pro-inflammatory cytokines such as tumor necrosis factor - α (TNF - α) and interleukin-6 (IL-6) in both acute and chronic inflammation models. Its fundamental function is to inhibit the activation of the core inflammatory pathway NF - κ B.
- Antitumor activity Studies have shown that methylisoalizarin can inhibit the proliferation and promote apoptosis of breast cancer, colon cancer, liver cancer, T-lymphocyte leukemia, cervical cancer and other cancer cells. Its anti-tumor effect has multi-target characteristics, not only inducing cancer cell apoptosis, but also possibly affecting the cell cycle.
- Anti osteoporosis activity This compound can specifically inhibit the differentiation and formation of osteoclasts, as well as their bone resorption function, thus demonstrating the potential for preventing and treating osteoporosis in cellular and animal models.
- Liver protective effect In the chemical liver injury model induced by carbon tetrachloride, methyl isorubicin effectively reduces liver cell necrosis and fibrosis through its antioxidant and anti-inflammatory properties, exhibiting liver protective effects.
- Antiviral and anti infective activity Methyl isorubicin can inhibit the replication of hepatitis B virus (HBV) DNA. At the same time, it has inhibitory effects on various fungi and bacteria, and exhibits anti malarial activity, indicating its broad-spectrum anti infective potential.
- Neuroprotection and Anticonvulsant In Alzheimer's disease related research, methyl isoquercetin has shown neuroprotective potential. In addition, it also has anticonvulsant activity and may be used in the study of epileptic seizures.
- Other activities In the model of diabetes nephropathy and iron overload disease, methylisoalizarin also showed improvement, suggesting its application prospect in metabolic and cumulative diseases.
Mechanism of action and molecular targets
The multiple pharmacological effects of methyl isorubicin stem from its regulation of complex cellular signaling networks, and its mechanism of action is closely related to multiple key molecular targets, especially in tumor research such as leukemia where the target network is relatively clear
- Core pathway: NF - κ B pathway inhibition Methylisorubicin inhibits the activity of I κ B kinase (IKK), prevents the phosphorylation and degradation of I κ B protein, and thus retains NF - κ B dimers in the cytoplasm, blocking their nuclear translocation and transcription of downstream inflammatory and survival factors. This is the core mechanism of its anti-inflammatory and partially anti-tumor effects.
- Energy and Metabolism Sensor: AMPK Activation Methyl isoquercetin can activate AMP activated protein kinase (AMPK, encoded by PRKAA1). The activation of AMPK can regulate cellular energy metabolism, inhibit synthetic metabolism, and inhibit cell proliferation and induce autophagy by phosphorylating downstream targets such as mTOR and ACC, playing a key role in anti-tumor and metabolic regulation.
- Apoptosis regulation: BCL-2 family proteins This compound can downregulate the expression of anti apoptotic proteins B cell lymphoma 2 (BCL-2) and myeloid leukemia 1 (MCL1), and may also affect pro apoptotic proteins, disrupt mitochondrial membrane potential, promote cytochrome C release, activate caspase cascade reaction, and induce cancer cell apoptosis.
- Signal Transduction and Transcription Activation Factor: STAT3 Inhibition Methylisorubicin can inhibit the phosphorylation (activation) of signal transduction and transcription activator 3 (STAT3). STAT3 is an important oncogenic transcription factor, whose sustained activation promotes cell proliferation, survival, and immune escape. Inhibition of STAT3 is an important mechanism for its anti-tumor effects, especially in the treatment of hematological malignancies.
- Other key targets：
- NOTCH1 Inhibiting the NOTCH1 signaling pathway, which is abnormally activated in diseases such as T-cell leukemia.
- SIRT1 It may affect cellular stress response and metabolism by regulating the deacetylase SIRT1.
- NFE2L2（Nrf2）Activation of the Nrf2 pathway may enhance cellular antioxidant defense capabilities, which is one of the mechanisms underlying its antioxidant and cell protective effects.
- MAPT (Tau protein) and IDH1 It suggests that it may intervene in the pathology of Tau protein or tumor metabolism in neurodegenerative diseases (related to IDH1 mutations).
- TOP1 May affect DNA topoisomerase I and interfere with DNA replication and repair.
In summary, methyl isoquercetin achieves its comprehensive biological effects of anti-inflammatory, antioxidant, pro apoptotic, and anti proliferative through the synergistic effect of "multi-target multi pathway".
Evaluation of drug properties and pharmacokinetics
Despite the wide pharmacological activity of methyl isoquercetin, its pharmacological development still faces challenges, and related research is still in its early stages.
- Absorption, distribution, metabolism, excretion (ADME)Due to its low solubility and moderate permeability, oral bioavailability may be limited. Its LogP value suggests that its distribution volume may be large, but its blood-brain barrier permeability is low, limiting its direct therapeutic effect on central nervous system diseases. As a derivative of anthraquinone, methyl isorubicin is expected to undergo extensive metabolism in vivo, mainly through phase I (such as hydroxylation, demethylation) and phase II (glucuronidation, sulfation) binding reactions in the liver. Metabolites are mainly excreted through bile and urine. At present, there is a lack of systematic human pharmacokinetic data, and there is an urgent need for in-depth research in animal models.
- Formulation strategy To improve its bioavailability, advanced drug delivery systems need to be developed. Potential strategies include: making nanocrystals, liposomes, solid dispersions, or cyclodextrin inclusion complexes to increase solubility and dissolution rate; Design prodrugs to improve their physicochemical properties; Or develop targeted delivery systems to increase drug concentration at lesion sites such as tumors.
- Preliminary Safety Assessment Based on existing data, its lack of hERG inhibition and lower risk of Ames mutagenesis are positive signals. However, the potential hepatorenal toxicity, photosensitivity, and laxative effects (depending on the structure) of natural anthraquinone compounds in long-term use need to be rigorously evaluated in their subsequent development.
Clinical application prospects and prospects
Methyl isoquercetin, as a multi-target natural lead compound, has broad development prospects in various disease fields, but there are also clear challenges.
-
Prospect areas：
- Inflammatory related diseases As an NF - κ B inhibitor, it can be used for the development of new drugs for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
- Adjuvant or combination therapy for tumor treatment Especially in hematological tumors that are resistant to existing chemotherapy drugs or have abnormal activation of STAT3 and NOTCH1 pathways (such as T-cell leukemia), it can be used as part of a combination therapy strategy to enhance efficacy or reverse drug resistance.
- Metabolic bone disease Its specific inhibition of osteoclasts makes it a potential candidate drug for the prevention and treatment of osteoporosis.
- anti-infection It may have application value in the adjuvant treatment of multidrug-resistant fungal or bacterial infections, as well as specific viral hepatitis.
- Chemical prevention Due to its antioxidant and anti-inflammatory properties, it may be used for chemoprevention of certain cancers or degenerative diseases.
-
Challenges and Future Directions：
- Deep analysis of the mechanism of action Chemical biological methods such as probe labeling and proteomics need to be used to more accurately identify its direct target and distinguish primary targets from secondary effects.
- Optimization of drug properties in the system Systematic preclinical pharmacokinetic and toxicological studies must be conducted, and reasonable chemical modifications or formulation innovations must be made based on their structure to address issues such as solubility, bioavailability, and targeting.
- Explore combination therapy Studying its synergistic effect with existing standard therapeutic drugs (such as chemotherapy drugs and targeted drugs) and exploring the optimal combination regimen may be a faster conversion pathway.
- Clinical research advancement Based on sufficient preclinical research, gradually advance to the clinical trial stage to verify its safety and effectiveness in humans.
Conclusion
Methyl isorubicin, as a structurally clear natural anthraquinone compound, exhibits outstanding multi pharmacological activities in multiple important disease fields such as anti-inflammatory, anti-tumor, anti osteoporosis, and anti infection due to its unique mode of action that inhibits the NF - κ B pathway as its core and widely regulates multiple key targets such as AMPK, STAT3, BCL-2, etc. Despite facing challenges in terms of solubility and bioavailability, its clear multi-target mechanism of action and good preliminary safety characteristics make it a highly valuable lead compound for development. Future research should focus on elucidating the precise target network within its cells, optimizing its pharmacokinetic properties through rational drug chemical modifications and novel delivery systems, and actively exploring its potential as a monotherapy or combination therapy in specific disease models and clinical studies. With the continuous deepening of research, methyl isoquercetin is expected to provide new natural drug candidate molecules or important structural optimization templates for the treatment of various refractory diseases.
